Literature DB >> 31403023

Multidisciplinary Treatment for Individuals at Clinical High Risk of Developing Psychosis.

Jean Addington1,2, Daniel J Devoe1,2, Olga Santesteban-Echarri1,2.   

Abstract

PURPOSE: One of the goals of identifying youth identified, based on clinical symptoms, as being at risk for developing psychosis, is to find ways to prevent or even delay the onset of the illness. Over the past 20 years, relatively few randomized control trials (RCTs), including both pharmacological and psychosocial interventions, have been conducted and often with inconsistent results. Several recent meta-analyses suggest that there are few treatments if any that might be effective and that no one treatment is seen as being more effective than any other treatment. This review aims to examine the existing RCTs and to critically review recent meta-analyses. RECENT
FINDINGS: Individuals at clinical high risk for psychosis are a heterogenous group. Unfortunately, many interventions have not been specifically designed to address the outcome being assessed nor have participants been specifically selected for that treatment.
SUMMARY: The trials completed to date and the recent systematic reviews should be seen positively and used to guide the design of future trials to ensure that the right interventions are offered to the right people at the right time.

Entities:  

Keywords:  clinical high risk; clinical trials; meta-analyses; prodrome; psychosis; treatment

Year:  2019        PMID: 31403023      PMCID: PMC6688178          DOI: 10.1007/s40501-019-0164-6

Source DB:  PubMed          Journal:  Curr Treat Options Psychiatry


  37 in total

1.  A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis.

Authors:  Jean Addington; Irvin Epstein; Lu Liu; Paul French; Katherine M Boydell; Robert B Zipursky
Journal:  Schizophr Res       Date:  2010-11-12       Impact factor: 4.939

2.  Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States.

Authors:  Alison R Yung; Hok Pan Yuen; Patrick D McGorry; Lisa J Phillips; Daniel Kelly; Margaret Dell'Olio; Shona M Francey; Elizabeth M Cosgrave; Eoin Killackey; Carrie Stanford; Katherine Godfrey; Joe Buckby
Journal:  Aust N Z J Psychiatry       Date:  2005 Nov-Dec       Impact factor: 5.744

3.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

4.  Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.

Authors:  Thomas H McGlashan; Robert B Zipursky; Diana Perkins; Jean Addington; Tandy Miller; Scott W Woods; Keith A Hawkins; Ralph E Hoffman; Adrian Preda; Irvin Epstein; Donald Addington; Stacy Lindborg; Quynh Trzaskoma; Mauricio Tohen; Alan Breier
Journal:  Am J Psychiatry       Date:  2006-05       Impact factor: 18.112

5.  Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?

Authors:  Alison R Yung; Hok Pan Yuen; Gregor Berger; Shona Francey; Te-Chieh Hung; Barnaby Nelson; Lisa Phillips; Patrick McGorry
Journal:  Schizophr Bull       Date:  2007-04-02       Impact factor: 9.306

6.  International clinical practice guidelines for early psychosis.

Authors: 
Journal:  Br J Psychiatry Suppl       Date:  2005-08

7.  Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Authors:  G Paul Amminger; Miriam R Schäfer; Konstantinos Papageorgiou; Claudia M Klier; Sue M Cotton; Susan M Harrigan; Andrew Mackinnon; Patrick D McGorry; Gregor E Berger
Journal:  Arch Gen Psychiatry       Date:  2010-02

8.  Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial.

Authors:  Anthony P Morrison; Paul French; Lara Walford; Shôn W Lewis; Aoiffe Kilcommons; Joanne Green; Sophie Parker; Richard P Bentall
Journal:  Br J Psychiatry       Date:  2004-10       Impact factor: 9.319

9.  Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.

Authors:  Patrick D McGorry; Alison R Yung; Lisa J Phillips; Hok Pan Yuen; Shona Francey; Elizabeth M Cosgrave; Dominic Germano; Jenny Bravin; Tony McDonald; Alison Blair; Stephen Adlard; Henry Jackson
Journal:  Arch Gen Psychiatry       Date:  2002-10

10.  Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis.

Authors:  S Ruhrmann; A Bechdolf; K-U Kühn; M Wagner; F Schultze-Lutter; B Janssen; K Maurer; H Häfner; W Gaebel; H-J Möller; W Maier; J Klosterkötter
Journal:  Br J Psychiatry Suppl       Date:  2007-12
View more
  7 in total

Review 1.  Attrition rates in trials for adolescents and young adults at clinical high-risk for psychosis: A systematic review and meta-analysis.

Authors:  Megan S Farris; Daniel J Devoe; Jean Addington
Journal:  Early Interv Psychiatry       Date:  2019-08-18       Impact factor: 2.732

2.  Telepsychotherapy with Youth at Clinical High Risk for Psychosis: Clinical Issues and Best Practices during the COVID-19 Pandemic.

Authors:  Joseph S DeLuca; Nicole D Andorko; Doha Chibani; Samantha Y Jay; Pamela J Rakhshan Rouhakhtar; Emily Petti; Mallory J Klaunig; Elizabeth C Thompson; Zachary B Millman; Kathleen M Connors; LeeAnn Akouri-Shan; John Fitzgerald; Samantha L Redman; Caroline Roemer; Miranda A Bridgwater; Jordan E DeVylder; Cheryl A King; Steven C Pitts; Shauna P Reinblatt; Heidi J Wehring; Kristin L Bussell; Natalee Solomon; Sarah M Edwards; Gloria M Reeves; Robert W Buchanan; Jason Schiffman
Journal:  J Psychother Integr       Date:  2020-06

3.  The Ohio State University Early Psychosis Intervention Center (EPICENTER) step-based care programme for individuals at clinical high risk for psychosis: study protocol for an observational study.

Authors:  Nicholas J K Breitborde; Hossam Guirgis; Walter Stearns; Kristen M Carpenter; Ghada Lteif; Jacob G Pine; Nichole Storey; Heather Wastler; Aubrey M Moe
Journal:  BMJ Open       Date:  2020-01-27       Impact factor: 2.692

Review 4.  Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art.

Authors:  Philip D Harvey; Marta Bosia; Roberto Cavallaro; Oliver D Howes; René S Kahn; Stefan Leucht; Daniel R Müller; Rafael Penadés; Antonio Vita
Journal:  Schizophr Res Cogn       Date:  2022-03-22

5.  A qualitative study on identity in individuals at clinical high risk for psychosis: " … Why does it have to be one thing?".

Authors:  Cansu Sarac; Joseph S DeLuca; Zarina R Bilgrami; Shaynna N Herrera; Jonathan J Myers; Matthew F Dobbs; Shalaila S Haas; Therese L Todd; Agrima Srivastava; Rachel Jespersen; Riaz B Shaik; Yulia Landa; Larry Davidson; Anthony J Pavlo; Cheryl M Corcoran
Journal:  Psychiatr Rehabil J       Date:  2021-06-17

6.  Depression: An actionable outcome for those at clinical high-risk.

Authors:  Jean Addington; Megan S Farris; Lu Liu; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Carrie E Bearden; Daniel H Mathalon; William S Stone; Matcheri Keshevan; Scott W Woods
Journal:  Schizophr Res       Date:  2020-10-29       Impact factor: 4.939

7.  Selection for psychosocial treatment for youth at clinical high risk for psychosis based on the North American Prodrome Longitudinal Study individualized risk calculator.

Authors:  Michelle A Worthington; David J Miklowitz; Mary O'Brien; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Barbara A Cornblatt; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Tyrone D Cannon
Journal:  Early Interv Psychiatry       Date:  2020-01-14       Impact factor: 2.732

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.